Authors:
CAPURRO M
BOVER L
PORTELA P
LIVINGSTON P
MORDOH J
Citation: M. Capurro et al., FC-2.15, A MONOCLONAL-ANTIBODY ACTIVE AGAINST HUMAN BREAST-CANCER, SPECIFICALLY RECOGNIZES LEWIS(X) HAPTEN, Cancer immunology and immunotherapy, 45(6), 1998, pp. 334-339
Authors:
BARRIO MM
BRAVO AI
PORTELA P
HERSEY P
MORDOH J
Citation: Mm. Barrio et al., A NEW EPITOPE ON HUMAN MELANOMA-ASSOCIATED ANTIGEN CD63 ME491 EXPRESSED BY BOTH PRIMARY AND METASTATIC MELANOMA/, Hybridoma, 17(4), 1998, pp. 355-364
Authors:
BALLARE C
PORTELA P
SCHIAFFI J
YOMHA R
MORDOH J
Citation: C. Ballare et al., REACTIVITY OF MONOCLONAL-ANTIBODY FC-2.15 AGAINST DRUG-RESISTANT BREAST-CANCER CELLS - ADDITIVE CYTOTOXICITY OF ADRIAMYCIN AND TAXOL WITH FC-2.15, Breast cancer research and treatment, 47(2), 1998, pp. 163-170
Authors:
BOVER L
BARRIO M
BRAVO AI
SLAVUTSKY I
LARRIPA I
BOLONDI A
AYALA M
MORDOH J
Citation: L. Bover et al., THE HUMAN BREAST-CANCER CELL-LINE IIB-BR-G HAS AMPLIFIED C-MYC AND C-FOS ONCOGENES IN-VITRO AND IS SPONTANEOUSLY METASTATIC IN-VIVO, Cellular and molecular biology, 44(3), 1998, pp. 493-504
Authors:
LEDDA MF
ADRIS S
BRAVO AI
KAIRIYAMA C
BOVER L
CHERNAJOVSKY Y
MORDOH J
PODHAJCER OL
Citation: Mf. Ledda et al., SUPPRESSION OF SPARC EXPRESSION BY ANTISENSE RNA ABROGATES THE TUMORIGENICITY OF HUMAN-MELANOMA CELLS, Nature medicine, 3(2), 1997, pp. 171-176
Citation: J. Mordoh et al., ALLOGENEIC CELLS VACCINE INCREASES DISEASE-FREE SURVIVAL IN STAGE-IIIMELANOMA PATIENTS - A NON RANDOMIZED PHASE-II STUDY, Medicina, 57(4), 1997, pp. 421-427
Authors:
LEDDA F
BRAVO AI
ADRIS S
BOVER L
MORDOH J
PODHAJCER OL
Citation: F. Ledda et al., THE EXPRESSION OF THE SECRETED PROTEIN ACIDIC AND RICH IN CYSTEINE (SPARC) IS ASSOCIATED WITH THE NEOPLASTIC PROGRESSION OF HUMAN-MELANOMA, Journal of investigative dermatology, 108(2), 1997, pp. 210-214
Authors:
LEDDA MF
ADRIS S
BRAVO AI
BOVER L
CARBONE C
PALEOLOG E
MORDOH J
CHERNAJOVSKY Y
PODHAJCER OL
Citation: Mf. Ledda et al., TUMOR-CELLS ENGINEERED TO EXPRESS INTERLEUKIN-6 EXHIBIT A REDUCED TUMORIGENICITY DEPENDING ON THE TUMOR-CELL MODEL, Cellular and molecular biology, 42(5), 1996, pp. 769-778
Citation: V. Morvillo et al., IDENTIFICATION AND CHARACTERIZATION OF A 14-KDA IMMUNOSUPPRESSIVE PROTEIN-DERIVED FROM IIB-MEL-J, A HUMAN-MELANOMA CELL-LINE, Cellular and molecular biology, 42(5), 1996, pp. 779-795
Authors:
MORDOH J
SILVA C
ALBARELLOS M
BRAVO AI
KAIRIYAMA C
Citation: J. Mordoh et al., PHASE-I CLINICAL-TRIAL IN CANCER-PATIENTS OF A NEW MONOCLONAL-ANTIBODY FC-2.15 REACTING WITH TUMOR PROLIFERATING CELLS, Journal of immunotherapy with emphasis on tumor immunology, 17(3), 1995, pp. 151-160
Authors:
KAIRIYAMA C
SLAVUTSKY I
LARRIPA I
MORVILLO V
BRAVO AI
BOVER L
PODHAJCER OL
MORDOH J
Citation: C. Kairiyama et al., BIOLOGIC, IMMUNOCYTOCHEMICAL, AND CYTOGENETIC CHARACTERIZATION OF 2 NEW HUMAN-MELANOMA CELL-LINES - IIB-MEL-LES AND IIB-MEL-IAN, Pigment cell research, 8(3), 1995, pp. 121-131
Citation: C. Ballare et al., FUNCTIONAL-PROPERTIES OF FC-2.15, A MONOCLONAL-ANTIBODY THAT MEDIATESHUMAN-COMPLEMENT CYTOTOXICITY AGAINST BREAST-CANCER CELLS, Cancer immunology and immunotherapy, 41(1), 1995, pp. 15-22
Authors:
PODHAJCER OL
BOVER L
BRAVO AI
LEDDA MF
KAIRIYAMA C
CALB I
GUERRA L
CAPONY F
MORDOH J
Citation: Ol. Podhajcer et al., EXPRESSION OF CATHEPSIN-D IN PRIMARY AND METASTATIC HUMAN-MELANOMA AND DYSPLASTIC NEVI, Journal of investigative dermatology, 104(3), 1995, pp. 340-344